MAVENIR
10.1.2022 09:02:11 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced that BAI Communications (BAI), a global communications infrastructure provider, will be launching a Smart City project for Sunderland City Council in the north of England (UK), powered by Mavenir’s MAVedge solution.
BAI Communications will build a new 5G centric network to accelerate adoption of transformative digital services for sectors including manufacturing and logistics, education and social care. The initial scope is for the deployment of a city-centre 5G private network which has the potential to evolve and become a neutral host network.
Neutral host models provide coverage and connectivity for smart city initiatives. They enable local councils and authorities to provide smart services and run numerous smart community applications in a more viable and cost-effective manner.
MAVedge comprises Mavenir’s leading edge Open vRAN and 5G Packet Core solutions to drive the next generation digital transformation of this Smart City project, and to provide advanced 5G mobile connectivity to the local Sunderland community. MAVedge enables secure private networks to be distributed at the edge and powers a digital marketplace of applications and devices to create an efficient environment for diverse use cases for the enterprise and industry.
The 5G Open vRAN and 5G Packet Core solutions are designed with cloud-native virtualisation techniques providing a fully scalable and virtualised network architecture with open standard interfaces. The Open RAN platform provides BAI Communications the option of deploying radio units from different vendors. The solution uses software running on commercial off the shelf (COTS) hardware that provides cost effectiveness, flexibility and agility, whilst delivering one architecture as a baseline for many different use cases.
The new network will help accelerate transformation within various sectors in Sunderland including:
- Smart Homes: addressing health and social care requirements supporting vulnerable individuals living in their own homes, providing access to assistive technologies such as sensors and other IoT enabled devices.
- Digital Skills and Education: providing enhanced online and remote connectivity and distance learning across Primary Schools and Secondary Schools within the local authority.
- Manufacturing and Industry 4.0: improving supply chain agility for the automotive industry, including applications such as self-driving vehicles and autonomous heavy goods vehicles.
“Open RAN is a cost-effective solution which is based on open interfaces and will give us the ability to deploy in a very agile and flexible way,” said Brendan O’Reilly, Group Chief Technology Officer at BAI Communications. “We are delighted to work with Mavenir, a technology innovator company in cloud-native virtualised solutions and a leading player in the Open RAN initiative and 5G Core. Technology we believe will help accelerate Sunderland’s ambitions to become one of the UK’s most advanced smart cities, connecting people, communities and businesses.”
“BAI Communications represents an ideal partner for this prestigious smart city project in Sunderland. Together, we will be able to build new RAN and Packet Core domains that will deliver the flexibility needed for a diverse set of cross-sector use cases. Virtualised solutions from Mavenir are the perfect choice of technology with Open vRAN and Cloud-Native Packet Core. The objective is to automate operations and flex the scalability in neutral hosting architecture, whilst delivering benefits not only to enterprises and business users, but also for the wider community,” said Stefano Cantarelli, Chief Marketing Officer at Mavenir.
“We are creating a new digital fabric for Sunderland’s City, upon which the City’s digital and business entrepreneurs can build – a portfolio of new digital services for the benefits of residents, businesses and visitors,” says Andrew Conway, Director of Solutions and Innovation at BAI Communications UK.
Liz St Louis, Assistant Director of Smart Cities at Sunderland City Council, said, “We have long recognised the importance of technology in connecting people and realising opportunities to position Sunderland as a digital frontrunner. This new partnership between BAI Communications and Mavenir presents a fully scalable network architecture to unlock innovation and shape the future of our leading smart city.
“Together, we are harnessing the power of technology and digital transformation for the benefit of residents, businesses and visitors to Sunderland. The new network will accelerate the emergence of more smart services including community applications, digital upskilling opportunities and efficiency drives for our advanced manufacturing clusters across the city.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About BAI Communications:
BAI Communications is a world leader in shared communications infrastructure, pioneering solutions that empower our customers to advance their services, accelerate their networks and amplify their reach in the most efficient and cost-effective ways possible. Having long been at the forefront of network advancement, BAI is harnessing fibre, spearheading the transition from 4G/LTE, accelerating 5G and preparing for 6G – and beyond. We collaborate closely with our customers in MNOs, government, transit, enterprise, broadcasting and venues to realise their communications vision, focusing not just on the immediate future, but on the possibilities that exist over long-term partnerships. Our global operations span Australia, Canada, Hong Kong, United Kingdom and in the United States through BAI Group company, Mobilitie , and majority-owned Transit Wireless . Together, we’re creating smarter communities for all. https://www.baicommunications.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005089/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom